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Abstract
Background: There are several mechanisms to describe allergic drug reactions yet the methods to diagnose them are limited.
Objective: To compare several conventional clinical and laboratory methods to diagnose skin reactions to drugs to a new
method of diagnosing drug reactions by the CellScan system.
Methods: The studyentailed 21patientswhowere diagnosed as suffering from drug eruptions, and 105 healthy controlswith
no history of drug allergy. The drugs were classiﬁed into two groups according to suspicion of causing drug allergy: high and
low. Most of the patients were on more than one drug, leading to 41 patient–drug interactions (assays). Histamine releasing
test (HRT), interferon (INF)-g releasing test and CellScan examination were performed on lymphocytes of the patients and
controls.
Results:TheHRTwasinterpretedaspositivein9outof18(50%)patientsandin13outof35(37%)assays.BasedontheINF-g
releasing test, positive resultswere observedin 16 out of21(76%) patientsand in24out of41(59%) assays. Inthe CellScan test
(CST),positive resultswereobservedin17outof21 (81%)patientsand in29out of41(71%)assays. Therate ofidentifyingthe
drugforeruptioninthehighsuspicionleveldrugswas9outof22(41%)assaysintheHRT,20outof24(83%)assaysintheINF-g
releasing test, and 21 out of 24 (87%) studies with the CellScan method. The rate of determining of the drug that caused the
eruptioninthelowsuspicionleveldrugswas4outof13(31%)intheHRT,4outof17(24%)assaysintheINF-greleasingtest,and
8outof17(47%)analysesintheCST.WhenexaminedintheCellScan,99outof105(94%)controlswereinterpretedasnegative.
Conclusion: This preliminary study indicates that the CellScan seems to be an easy and promising method for the detection of
drugsresponsibleforadverseskinreactions.IncontrasttotheHRTandtotheInterferon-gsecretiontest,theCellScanmethodis
characterizedbyitsabilitytotrackandmonitorthereactionofindividualcells.Bymeasuringthekineticparametersofselectedcells
before and after adding the suspected drug, we were able to identify the culprit drug. The CellScan method had the highest
sensitivity,andtheinterferon-gsecretiontesthadthehighestspeciﬁcityfordetectionoftheculpritdrug.Incontrast,theanalysisof
105 normal control sera disclosed a high speciﬁcity of 94% for the CellScan method.
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Introduction
Adverse reactions to drugs or biological agents are
frequent consequences of medical therapy, since few if
anymedicationsarefreeofadverseeffects.Allergicand
otherimmunologicaldrugreactions(typeBreactions),
cause up to 24% of the observed adverse drug
reactions, in a primarily in-patient population
(Lazarou et al. 1998). For most drugs, the risk of an
allergicreactionis1–3percent(DeSwarteetal.1993).
Between 2 and 24% (mean 11%) of hospitalized
patientsexperienceadversedrugreactions(ADR),and
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is 4.7% (Lazarou et al. 1998). Fatalities occur in 1 of
10,000 allergic drug reactions (Boston Collaborative
Drug Surveillance Program 1973), and they are
reported in 0.01% of the surgical inpatients and in
0.1% of the medical inpatients (Armstrong et al. 1976,
Porter and Jick 1977). A meta-analysis of 39
prospective studies on the incidence of ADR in
hospitalized patients over a period of 30 years
concluded that fatal reactions ranked between the
fourth and sixth leading cause of death in the United
States (Lazarou et al. 1998).
Cutaneous reactions are the most common mani-
festationofdrugreactions,andincludemaculopapular
eruptions, urticaria, angioedema, bullous exfoliative
rashes, photosensitivity reactions, ﬁxeddrug eruptions
and leucocytoclastic vasculitis (Shefferd 2003).
The clinical diagnosis of drug-induced skin reac-
tions is not an easy task. On the one hand the allergic
reaction may present in different and variable skin
manifestations. On the other hand, skin reactions
may mimic non-allergic skin diseases (Halevy and
Feuerman 1984, Brenner et al. 1998). Other
confounding factors inthe task of diagnosing drug-
induced skin reactions are the frequent polypharmacy
patients are exposed to, and the latent period that can
last from days to months, between taking the drug and
the appearance of the skin reaction.
To date reliable tests that conﬁrm allergic reaction
exist only for selected drugs (e.g. standardized skin
test for penicillin and local anesthetics, speciﬁc IgE,
patch test). In the vast majority of drug reactions,
diagnosis is based on clinical parameters and lacks
objective conﬁrmation. Challenge tests are poten-
tially hazardous and in most clinical situations are
not recommended. Due to these limitations several
in vitro tests have been developed, with the intent to
elucidate the different mechanisms of drug reactions,
and to provide evidence for the association between
a suspected drug and the adverse reaction (Wide and
Juhlin 1971, Gimenez-Camarasa et al. 1975, Watson
et al. 1978, Shoenfeld et al. 1980, Shoenfeld 1982,
Grunwald et al. 1989, Halevy et al. 1991, Halevy
et al. 2001, Sachs et al. 2001, Goldberg et al. 2004).
The value of these in vitro tests are also limited in
that the parent drug is used, and reactions occurring
to drugs metabolites or to the drug associated with
carrier proteins, are missed.
To date no objective method exists with enough
sensitivity and speciﬁcity to objectively diagnose drug
reactions, and there is no gold standard test to
compare the results of different assays.
The aim of this study was to compare conventional
clinical and laboratory methods used for the diagnosis
of drug-induced skin reactions, such as the histamine
releasing test (HRT) and to the Interferon-g secretion
test, and to introduce a novel method of diagnosing
drug reactions employing the CellScan system. In
contrast to the HRTand to the Interferon-g secretion
test, the CellScan method enables tracking and
monitoring of the reaction of individual cells. As
such, analysis can be performed to characterize
individual cell behavior, and its kinetics under
different conditions or drug exposure.
Patients and methods
Patients
Patients were selected after they presented with skin
reactions compatible with drug eruptions, after
exposure to different drugs. The suspected drugs
were classiﬁed into two groups, high and low level of
suspicion, based upon established parameters in drug-
allergy clinical practice including: (1) the prevalence
of allergic skin reactions for the speciﬁc drug; (2) the
temporal relationship between drug exposure and the
development of the skin rash; (3) the exclusion of
other medical conditions or drugs that can mimic the
speciﬁc skin reaction (Adkinson 2003). Most of the
patients were exposed to more than one drug, and for
every drug a separate evaluation was performed.
Sera from 105 healthy asymptomatic adults were
used as negative controls for the CellScan test (CST).
Histamine releasing test
The HRT is based on the measurement of histamine
released from guinea pig mast cells after incubation
with the patient’s serum and the suspected drug.
Brieﬂy, venous blood was collected from the patients.
Guinea pig mast cells were incubated for 60min. with
the patient’s serum and guinea pig’s serum as a
control. Next the suspected drug was added for an
additional 15min. of incubation. Following the
incubation, the supernatants were collected for the
detection of histamine secretion by the ELISA
technique (Immunotech, Westbrook ME, USA).
†
The test was interpreted as the number of degranu-
lated cells in the presence of the drug, compared to the
cells in the absence of the drug (the difference in
percentage). Negative result was determined when the
value was between 0 and 20%, borderline: 21–27%,
weak positive: 28–30%, positive: over 31%.
In Vitro interferon-g release Test (IRT)
The technique of in vitro INF-g releasing test was used
according to the method published by Halevy et al.
(1998). Brieﬂy, the patient’s lymphocytes were
cultured for 24h in a medium containing PHA-P, 5%
†ELISA tech for histamine.
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(unmodiﬁed and dissolved in the appropriate solvent).
Following incubation, the supernatants were collected
for the detection ofIFN-gusing acomercial ELISA kit
(Quantikine kit, R & D Systems, Minneapolis,USA).
For each drug the increase in IFN-g release
(in percentage) was calculated.
CellScan test
The CellScan apparatus is a laser scanning cytometer
incorporatingauniquecellcarrierthatallowsrepeated,
high-precision ﬂuorescence intensity (FI) and ﬂuor-
escencepolarization(FP)measurementstobemadeon
intact living cells under physiological conditions
(Deutsch and Weinreb 1994, Kaplan et al. 1997).
The CellScan is unique in its capability of repetitive
measurementsofindividualcellsinacellpopulation.It
has been used to detect activation of lymphocytes both
in physiological (Eisenthal et al. 1996, Zurgil et al.
1996) and pathological situations including: cancer
(Ron et al. 1995, Merimsky et al. 1996, Rahmani et al.
1996, Schiffenbauer et al. 2002, Cohen et al. 2003),
autoimmune disorders (Zurgil et al. 1997, Zurgil et al.
1999), and atherosclerosis (Zurgil et al. 1999).
Loading cells onto the cellcarrier. The cellcarrier was
placed on a specially designed loader. By tightening
the screws of the cell loader on the silicon plugs, a
small positive pressure in the buffer chamber was
created. Most of the drop that was formed on the top
of the cellcarrier was removed by suction. After a drop
of the cell suspension was added to the cellcarrier,
the screws were gradually released, and cells were
siphoned into the traps.The remaining cell suspension
was removed, and replaced with fresh buffer.
Measurement of ﬂuorescence polarization changes by
cellScan induced by different drugs stimulus.T h e
polarization of a molecule is proportional to the
molecule’s rotational relaxation time, which is related
to viscosity (h), absolute temperature (T), molecular
volume (V), and the gas constant (R). Rotational
relaxation time ¼ 3hV=RT: Therefore, at a given
temperature, changes in viscosity or molecular volume
as a result of degradation, binding, dissociation or
conformational changes will be reﬂected in the
polarization value. Speciﬁcally, after incubation with
the appropriate antigen, the cells were stained with
ﬂuorescein diacetate (FDA), which is a lipophilic,
uncharged, and a non-ﬂuorescent esther that can
readily cross cell membranes. Once inside the cell, it is
hydrolyzed by non-speciﬁc esterases to produce the
ﬂuoresceinanion,whichisretainedbylivingcellsandis
lost by cells with damaged membranes. Changes in
viscosity of the cytoplasm as a result of cell activation
lead to (FDA) depolarization.
The cells from the patient’s and from the control’s
groups were incubated with or without the corre-
sponding drugs for 30min at 378C in a humidiﬁed
atmosphere containing 5% CO2. Next, they were
stained for 5min with FDA at a ﬁnal concentration of
2.4mM, loaded onto the Cellcarrier, washed twice
with PBS, and FP was measured. Reduction in
intracellular FP of cells after antigenic stimuli in
comparison to unstimulated cells reﬂect the extension
of cell activation. Results of CellScan examination
were expressed as mean % of stimulation ^ standard
deviation ðMean ^ SDÞ.
Results
Twenty-one patients, 12 women and 9 men, with an
averageageof65wererecruitedtothisstudy.Themost
common allergic skin presentation associated with
drug exposure was maculopapular rash (11 patients),
followed by urticaria and/or angioedema (8 patients).
Two patients presented with bullous rashes. None of
the patients were hospitalized and all the patients were
followed in our outpatient clinic until full resolution of
the adversereactions.Median timeto full recoverywas
ten days. There were no fatalities among our patients.
Twenty-onepatientswereevaluatedfor41suspected
drug reactions, and Table I summarizes the demo-
graphic data of the study population. Eight patients
were exposed to one drug only, and only one drug was
analyzed. Thirteen patients were exposed to multiple
drugs:sevenpatientstotwodrugs,ﬁvepatientstothree
drugs and in one patient four possible drugs were
evaluated (Table II). Among the 21 patients with
suspected drug-induced skin reactions, in 18 patients,
the three different assays were used, and in the
remaining three patients due to technical reasons only
INF-g release test and Cellscan were compared.
For each test we calculated the total number of
patients with positive results, the total number of
assays that were positive (Table III), and the number
of positive results for each assay in relation to the
clinical suspicion (Table IV).
Histamine releasing test
Positive results were observed in 9 out of 18 (50%)
patients and in 13 out of 35 (37%) assays. In drugs
with high clinical suspicion 9 out of 22 (41%) assays
were positive, and 2 out of 13 (31%) assays were
positive in low clinical suspicion drugs.
INF-g releasing test
The test was positive in 16 out of 21 (76%) patients,
and in 24 out of 41 (59%) assays. When results were
stratiﬁed according to high or low clinical suspicion 20
out of 24 high clinical suspicion drugs gave positive
results (83%), compared to 4 positive results among
17 low clinical suspicion drugs (24%).
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Using the CellScan technique 17 out of 21 (81%)
patients had positive results, and 29 out of 41 (71%)
assays were interpreted as positive. These results
increased for high suspicion drugs where 21 out
of 24 (87%) of assays were positive. For the
low-suspicion drugs 8 out of 17 (47%) gave positive
results.
The rate of identiﬁcation of the drug that caused the
eruption in the high suspicion level drugs was 9 out of
22 (41%) assays in the histamine release test, 20 out of
24 (83%) assays in the interferon release test, and 21
out of 24 (87%) assays in the CST (Table III). In the
low suspicion level drugs, the rate of identiﬁcation of
the drug that caused the eruption was 4 out of 13
(31%) assays in the histamine release test, 4 out of 17
(24%) assays in the interferon release test, and 8 out of
17 (47%) assays in the CST (Table IV).
Controls
Ninety-nine out of 105 (94%) controls were negative
using the CST.
Table I. Patients’ demographics, skin reactions, drug exposure and tests results.
No. Age Sex Reaction* Drug IFN g Histamine CellScan Suspicion
1 62 F Mac pap Coumarin P P N H
2 48 F Mac pap Cefuroxime P P P H
Roxythrocine P P P H
Oﬂoxacin P P N L
3 57 M Mac pap Atenolol P N P H
Sod.valproate N N N L
4 82 M Mac pap Phenytoin N N P H
5 76 M Mac pap Simvastatin N N N L
Cilazapril P N P H
Aspirin N N P L
6 70 M Mac pap Rofecoxib P N P H
7 45 F Bullous Benazepril P – P H
Metformin P – N L
Timolol N – P L
8 64 F Urticaria Amoxycillin N N P H
Paracetamol P P N H
Famotidine P P P H
9 82 F Mac pap Cilazapril P P P H
Simvastatin P N P H
Paracetamol N P P L
Nifedipine N N N L
10 83 F Urticaria Pseudoephedrine P P N H
11 24 M Rash Pergonal N N P L
Bromocriptine P N P H
12 70 F Rash Fosinopril N P P H
13 67 M Rash Aspirin P N P H
Aspirin P N P H
14 46 F Rash Phenazopyridine N N P L
Ibuprofen P N P H
Cefuroxime N P N L
15 79 F Rash Enalapril N N P L
16 75 F Rash Simvastatin N N P L
Ramipril N P P H
17 88 M Rash Indometacin P P N L
18 68 M Rash Penicillin P N P H
Erythromycin P N P H
19 70 M Simvastatin P N P H
Enalapril N N P L
20 55 F AGEP Acetaminophen P NE P H
Dipyrone P NE N L
21 59 F Bullous Colchicines N NE N L
P–positive, N–negative, H–high clinical suspicion, L–low clinical suspicion.
*Mac Pap–Maculopapaular rash, AGEP–acute generalized exanthematous pustulosis.
Table II. Drug exposure by number of patients who developed
adverse drug reactions.
Number of patients Number of drugs
81
72
53
14
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Adverse reactions to pharmaceutical and diagnostic
products constitute a major hazard in the practice of
medicine and are responsible for substantial morbidity
and cost (Adkinson 2003). Currently, there are no
highly speciﬁc tests that are predictive either of the
capacityofnovelcompounds(drugs)toinduceallergic
reactions, or of the susceptibility of individuals to
experience allergic reaction. In vitro cytokine release
mayhaveadiagnosticroleincutaneousdrugeruptions.
In delayed type hypersensitivity reactions (type IV)
Th1 lymphocytes are activated and produce IL-2 and
interferon-g, whereas in immediate (type I) hyper-
sensitivityreactionsTh2lymphocytesareactivatedand
produce IL-4, IL-5 and IL-10, which are responsible
for speciﬁc IgE production. Recent studies have
demonstrated the diagnostic potential of a new test
basedonreleaseofinterferon-gfromlymphocytesafter
exposure to a suspected drug with a sensitivity of 54%
and speciﬁcity of 92% (Halevy et al. 2001).
In the present study we compared the HRTand the
interferon-g secretion test to a novel cell-based
technology, for the diagnosis of suspected drug-
induced skin reactions. Analysis of the performance
of the three tests in detecting drugs responsible for
skin reactions, based on the clinical suspicion
disclosed a low sensitivity (41%) and speciﬁcity
(69%) for the HRT, a relative high sensitivity (83%)
and moderate speciﬁcity (76%) for the Interferon-g
secretion test, and a high sensitivity (87%) and
moderate-low speciﬁcity (53%) for the CellScan (see
Table IV). The CellScan method had the highest
sensitivity, and the interferon-g secretion test had the
highest speciﬁcity for detection of the culprit drug.
In contrast, the analysis of 105 normal control sera
disclosed a high speciﬁcity of 94% for the CellScan
method.
In contrast to the HRT and to the Interferon-g
secretion test, the CellScan method is characterized by
its ability to track and monitor the reaction of
individual cells. As such, analysis can be performed
to characterize individual cell behavior, thus establish-
ing its kinetic trends. Kinetic approaches are valuable
tools for biological studies of cell function. By
measuring the kinetic parameters of selected cells
before and after adding the suspected drug, we were
able to identify the culprit drug.
It is clear that the future direction of predictive drug
allergy testing is not with animal tests (that are a
poor indicator of human responses) but with the use of
in vitro human cell culture systems that model the
human in vivo immune response. Our preliminary
study indicates that the CellScan seems to be a
promising method for the detection of drugs
responsible for adverse skin reactions.
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